B. Kutima

发表

SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021

J. Scott, C. Agoti, P. Bejon, 2022, medRxiv.

Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations

J. Scott, P. Bejon, I. Adetifa, 2021, Journal of Clinical Virology.

Kinetics of naturally induced binding and neutralizing anti-SARS-CoV-2 antibody levels and potencies among Kenyan patients with diverse grades of COVID-19 severity

E. Nduati, G. Warimwe, A. Abdi, 2022, medRxiv.

Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro

E. Nduati, J. Scott, C. Agoti, 2022, International Journal of Infectious Diseases.

Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

E. Nduati, C. Agoti, P. Bejon, 2023, Wellcome Open Research.

Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya

C. Agoti, D. Nokes, G. Githinji, 2022, Wellcome open research.

Kinetics of naturally induced binding and neutralising anti-SARS-CoV-2 antibody levels and potencies among SARS-CoV-2 infected Kenyans with diverse grades of COVID-19 severity: an observational study

E. Nduati, P. Bejon, S. Sayed, 2023, Wellcome Open Research.

SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-June 2022

J. Scott, M. Kimani, I. Adetifa, 2022, medRxiv.

SARS‐CoV‐2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February–December 2022

M. Kimani, P. Bejon, I. Adetifa, 2023, Influenza and other respiratory viruses.